Pfizer has partnered with a ‘computation-driven’ pharmaceutical technology company to develop a drug discovery platform powered by artificial intelligence (AI). Its collaboration with ...

An experimental antidepressant in development at Gate Neurosciences has started a proof-of-concept study to see if its efficacy can be boosted by a digital neurocognitive training tool. The study ...

UK Health Secretary West Streeting has announced plans for a national strategy for men's health, tackling issues "affecting men of all ages that are costing lives." The aim is to address diseases ...

Advanz Pharma's bid to keep its Ocaliva treatment for rare liver disease primary biliary cholangitis (PBC) on the EU market has ended in failure. The European Commission revoked the conditional ...

Healthcare professionals (HCPs) expect digital experiences to be as seamless and personalised as the apps and services they use in their daily lives. It’s essential that pharmaceutical ...

With Merck’s oral PCSK9 inhibitor demonstrating strong phase 3 trial results, J&J’s IL23R antagonist peptide continuing its phase 3 journey, and Chugai advancing peptides into the ...

uniQure says it has reached an agreement with the FDA on a pathway to accelerated approval for its Huntington's disease gene therapy based on a phase 1/2 trial. The announcement led to a doubling ...

President-Elect Donald Trump has revealed his pick to lead the National Institutes of Health (NIH), completing the roster of appointments that will be charged with fulfilling his 'Make America ...

Another clinical trial has found that SIGA Technologies' antiviral drug tecovirimat is ineffective as a treatment for mpox, prompting the investigators to stop patient recruitment. The study by ...

Novartis has made a dramatic return to the Huntington's disease therapy stage by licensing a candidate from PTC Therapeutics for a whopping $1 billion upfront. The deal – which has a potential ...

Eli Lilly will spend $3 billion expanding a recently acquired manufacturing facility in Wisconsin to provide capacity for injectable products, including its fast-growing obesity and diabetes drugs.

The CAR-T landscape has quickly transformed from a pioneering breakthrough to a highly competitive and evolving market. Ben Hargreaves finds that the early leaders, Gilead and Novartis, are now ...